On September 21, 2017, significant amendments were made to the Patent Act and the Patented Medicines (Notice of Compliance) Regulations to replace the summary judgment proceedings under the Regulations with full actions. Six months have now passed, and several cases have been started under the new Regulations. Please join the TIPG and our panelists, Prothonotary Kevin Aalto, Kristin Wall and Nathaniel Lipkus, for a discussion of the impact of the new Regulations on the Federal Court and the generic and innovative industries.
Prothonotary Aalto was appointed a Prothonotary of the Federal Court on May 7, 2007. He is a frequent speaker at various Continuing Legal Education seminars presented by the Law Society of Ontario, the Ontario Bar Association, Osgoode Hall Law School Professional Development and The Advocates’ Society, and is a member of many bench and bar committees dealing with Case Management and Access to Justice issues.
Kristin Wall is a partner with Norton Rose Fulbright Canada and practices in intellectual property law as a barrister and solicitor. She has particular experience with matters involving the innovative pharmaceutical industry, including litigation proceedings under the Patented Medicines (Notice of Compliance) Regulations and Food and Drug Regulations. Kristin is counsel on the first case to be brought under new Regulations.
Nathaniel Lipkus is a partner with Osler, Hoskin & Harcourt LLP and an intellectual property litigator. His practice focuses on contentious legal issues confronting innovation-intensive industries, with an emphasis on patent and regulatory issues facing pharmaceutical and biotechnology companies. Nathaniel is counsel on one of the first cases to be brought under new Regulations.
